Addex Total Liab from 2010 to 2024

ADXN Stock  USD 7.82  0.33  4.05%   
Addex Therapeutics Total Liabilities yearly trend continues to be very stable with very little volatility. Total Liabilities is likely to grow to about 4.5 M this year. Total Liabilities is the total amount of all liabilities that Addex Therapeutics has, including both short-term and long-term liabilities. View All Fundamentals
 
Total Liabilities  
First Reported
2009-12-31
Previous Quarter
M
Current Value
1.1 M
Quarterly Volatility
2.7 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Addex Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Addex Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 290.7 K, Interest Expense of 20.5 K or Total Revenue of 2.7 M, as well as many indicators such as Price To Sales Ratio of 2.01, Dividend Yield of 0.0 or PTB Ratio of 2.83. Addex financial statements analysis is a perfect complement when working with Addex Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Addex Therapeutics Correlation against competitors.
To learn how to invest in Addex Stock, please use our How to Invest in Addex Therapeutics guide.

Latest Addex Therapeutics' Total Liab Growth Pattern

Below is the plot of the Total Liab of Addex Therapeutics over the last few years. It is the total amount of all liabilities that a company has, including both short-term and long-term liabilities. Addex Therapeutics' Total Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Addex Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Total Liab10 Years Trend
Very volatile
   Total Liab   
       Timeline  

Addex Total Liab Regression Statistics

Arithmetic Mean4,079,722
Geometric Mean3,447,829
Coefficient Of Variation58.89
Mean Deviation1,851,600
Median3,496,420
Standard Deviation2,402,547
Sample Variance5.8T
Range8.6M
R-Value(0.06)
Mean Square Error6.2T
R-Squared0
Significance0.84
Slope(30,637)
Total Sum of Squares80.8T

Addex Total Liab History

20244.5 M
20233.5 M
20223.4 M
20215.6 M
20205.6 M
20197.5 M
2018M

About Addex Therapeutics Financial Statements

Addex Therapeutics investors utilize fundamental indicators, such as Total Liab, to predict how Addex Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Total Liabilities3.5 M4.5 M

Pair Trading with Addex Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Addex Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Addex Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Addex Stock

  0.71JNJ Johnson Johnson Fiscal Year End 28th of January 2025 PairCorr
  0.63LLY Eli LillyPairCorr
  0.73PFE Pfizer Inc Aggressive PushPairCorr

Moving against Addex Stock

  0.76GLABF Gemina LaboratoriesPairCorr
  0.69LFCR Lifecore BiomedicalPairCorr
  0.63BMY Bristol Myers SquibbPairCorr
  0.49KMDA KamadaPairCorr
  0.36CTLT CatalentPairCorr
The ability to find closely correlated positions to Addex Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Addex Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Addex Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Addex Therapeutics to buy it.
The correlation of Addex Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Addex Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Addex Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Addex Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Addex Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Addex Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Addex Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Addex Therapeutics Stock:
Check out the analysis of Addex Therapeutics Correlation against competitors.
To learn how to invest in Addex Stock, please use our How to Invest in Addex Therapeutics guide.
You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Addex Therapeutics. If investors know Addex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Addex Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(21.86)
Revenue Per Share
1.2
Quarterly Revenue Growth
(0.82)
Return On Assets
(0.62)
Return On Equity
(1.26)
The market value of Addex Therapeutics is measured differently than its book value, which is the value of Addex that is recorded on the company's balance sheet. Investors also form their own opinion of Addex Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Addex Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Addex Therapeutics' market value can be influenced by many factors that don't directly affect Addex Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Addex Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Addex Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Addex Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.